Transgene shares up on positive cancer vax data

Shares of France's Transgene jumped about 10 percent on Monday after new data from a Phase IIb trial of TG4010 demonstrated a survival benefit for non-small cell lung cancer patients. The French biotech noted that 39 percent of the patients receiving the vaccine combined with chemotherapy were still alive after 17 months of median follow-up, compared to 23 percent of the patients receiving chemotherapy alone.

A subpopulation of patients with a normal blood level of Natural Killer cells did even better. Researchers say they had an increased median survival rate of 6.7 months.

"We are delighted by the additional clinical data announced today, which once again validates our technological platform of immunotherapeutic products and our past investment in TG4010," said CEO Philippe Archinard. "Overall, these results are extremely promising."

- read the press release

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.